CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia

Abstract Introduction Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits. The decision to deprescribe cogni...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nathan Herrmann, Zahinoor Ismail, Rhonda Collins, Philippe Desmarais, Zahra Goodarzi, Alexandre Henri‐Bhargava, Andrea Iaboni, Julia Kirkham, Fadi Massoud, Andrea Moser, James Silvius, Jennifer Watt, Dallas Seitz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-01-01
coleção:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Assuntos:	cholinesterase inhibitor memantine cognitive enhancer dementia deprescribing discontinuation
Acesso em linha:	https://doi.org/10.1002/trc2.12099
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!